The Absolute Effect / Evidence index
Advanced / Metastatic · Phase III randomized noninferiority; N=748 RAS/BRAF wild-type unresectable mCRC. Anlotinib+CapeOX vs bevacizumab+CapeOX; primary endpoint independent-review PFS; HR noninferiority margin 1.09. · Median PFS 11.0 vs 11.0 months
ANCHOR
Clinical question: Is anlotinib plus CapeOX noninferior to bevacizumab plus CapeOX in first-line RAS/BRAF-wild-type metastatic colorectal cancer?
Median PFS 11.0 vs 11.0 months; HR 1.00 (95% CI 0.84–1.18; P=0.87). Prespecified noninferiority criterion not met. · Registry:
Design, population and treatment
Phase III randomized noninferiority; N=748 RAS/BRAF wild-type unresectable mCRC. Anlotinib+CapeOX vs bevacizumab+CapeOX; primary endpoint independent-review PFS; HR noninferiority margin 1.09.
Key efficacy outcome
Grade ≥3 treatment-related AEs 64.9% vs 44.8%; approximate NNH 5.
Safety and absolute effect
Median PFS (months)
https://www.nature.com/articles/s41392-026-02938-4
Interpretation and limitations
Current-practice context · 14 November 2026: Primary publication/abstract and trial identifier checked. Guideline-level current-practice mapping was not established in this publication-led batch; no NCCN citation provenance is claimed. Where detailed QoL, follow-up or toxicity data were not present in the retrieved abstract, they are not inferred.